210 related articles for article (PubMed ID: 7530159)
1. Competitive binding experiments reveal differential interactions for dihydropyridine calcium channel activators and antagonists at dihydropyridine receptors on mouse brain membranes.
O'Neill SK; Triggle CR; Bolger GT
Can J Physiol Pharmacol; 1994 Jul; 72(7):738-45. PubMed ID: 7530159
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the properties of binding of calcium-channel activators and inhibitors to dihydropyridine receptors in chick heart membranes.
Maan AC; Hosey MM
Circ Res; 1987 Sep; 61(3):379-88. PubMed ID: 2441891
[TBL] [Abstract][Full Text] [Related]
3. Comparative behavioral, neurochemical and pharmacological activities of dihydropyridine calcium channel activating drugs.
O'Neill SK; McKay DW; Campbell N; Triggle CR; Crowley M; Bolger GT
J Pharmacol Exp Ther; 1990 Jun; 253(3):905-12. PubMed ID: 1694243
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activator-antagonist pairs in smooth muscle.
Wei XY; Luchowski EM; Rutledge A; Su CM; Triggle DJ
J Pharmacol Exp Ther; 1986 Oct; 239(1):144-53. PubMed ID: 2428971
[TBL] [Abstract][Full Text] [Related]
5. The effects of strychnine on the regulation of voltage-dependent calcium channels by dihydropyridines in brain and heart.
O'Neill SK; Bolger GT
Pharmacol Biochem Behav; 1990 Apr; 35(4):833-40. PubMed ID: 1693213
[TBL] [Abstract][Full Text] [Related]
6. Dihydropyridine-sensitive Ca2+ channels: molecular properties of interaction with Ca2+ channel blockers, purification, subunit structure, and differentiation.
Lazdunski M; Barhanin J; Borsotto M; Fosset M; Galizzi JP; Renaud JF; Romey G; Schmid A
J Cardiovasc Pharmacol; 1986; 8 Suppl 8():S13-9. PubMed ID: 2433514
[TBL] [Abstract][Full Text] [Related]
7. Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists.
Zahradníková A; Minarovic I; Zahradník I
J Pharmacol Exp Ther; 2007 Aug; 322(2):638-45. PubMed ID: 17475903
[TBL] [Abstract][Full Text] [Related]
8. Specific binding of a calcium channel activator, [3H]BAY k 8644, to membranes from cardiac muscle and brain.
Janis RA; Rampe D; Sarmiento JG; Triggle DJ
Biochem Biophys Res Commun; 1984 May; 121(1):317-23. PubMed ID: 6203531
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of binding of dihydropyridine calcium channel ligands to skeletal muscle membranes: evidence for low-affinity sites and for the involvement of G proteins.
Dunn SM; Bladen C
Biochemistry; 1991 Jun; 30(23):5716-21. PubMed ID: 1645998
[TBL] [Abstract][Full Text] [Related]
10. Influence of Mg++ on the effect of diltiazem to increase dihydropyridine binding to receptors on Ca++-channels in chick cardiac and skeletal muscle membranes.
Maan AC; Ptasienski J; Hosey MM
J Pharmacol Exp Ther; 1986 Dec; 239(3):768-74. PubMed ID: 2432217
[TBL] [Abstract][Full Text] [Related]
11. Effects of N- and L-type calcium channel antagonists and (+/-)-Bay K8644 on nerve-induced catecholamine secretion from bovine perfused adrenal glands.
O'Farrell M; Ziogas J; Marley PD
Br J Pharmacol; 1997 Jun; 121(3):381-8. PubMed ID: 9179377
[TBL] [Abstract][Full Text] [Related]
12. Binding of the dihydropyridine calcium channel blocker (+)-[3H] isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2, 6-dimethyl-3-pyridinecarboxylate (PN200-110) to RINm5F membranes and cells: characterization and functional significance.
Yaney GC; Stafford GA; Henstenberg JD; Sharp GW; Weiland GA
J Pharmacol Exp Ther; 1991 Aug; 258(2):652-62. PubMed ID: 1713965
[TBL] [Abstract][Full Text] [Related]
13. Enantiomer selectivity and the development of tolerance to the behavioral effects of the calcium channel activator BAY K 8644.
O'Neill SK; Bolger GT
Brain Res Bull; 1988 Dec; 21(6):865-72. PubMed ID: 2465070
[TBL] [Abstract][Full Text] [Related]
14. Calcium channel 'agonist' BAY K 8644 inhibits calcium antagonist binding to brain and PC12 cell membranes.
Greenberg DA; Cooper EC; Carpenter CL
Brain Res; 1984 Jul; 305(2):365-8. PubMed ID: 6204725
[TBL] [Abstract][Full Text] [Related]
15. Two calcium channels in basolateral membranes of rabbit ileal epithelial cells.
Homaidan FR; Donowitz M; Weiland GA; Sharp GW
Am J Physiol; 1989 Jul; 257(1 Pt 1):G86-93. PubMed ID: 2473655
[TBL] [Abstract][Full Text] [Related]
16. Selective antagonism of calcium channel activators by fluspirilene.
Kenny BA; Fraser S; Kilpatrick AT; Spedding M
Br J Pharmacol; 1990 Jun; 100(2):211-6. PubMed ID: 1696149
[TBL] [Abstract][Full Text] [Related]
17. [3H]diltiazem binding to calcium channel antagonists recognition sites in rat cerebral cortex.
Schoemaker H; Langer SZ
Eur J Pharmacol; 1985 May; 111(2):273-7. PubMed ID: 2410283
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the calcium channel activating 3H-BAY K 8644 and inhibiting 3H-verapamil with specific receptor sites on cultured beating myocardial cells.
Bellemann P
J Recept Res; 1984; 4(1-6):571-85. PubMed ID: 6084713
[TBL] [Abstract][Full Text] [Related]
19. Separate [3H]-nitrendipine binding sites in mitochondria and plasma membranes of bovine adrenal medulla.
Ballesta JJ; Garcia AG; Gutierrez LM; Hidalgo MJ; Palmero M; Reig JA; Viniegra S
Br J Pharmacol; 1990 Sep; 101(1):21-6. PubMed ID: 1704272
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of the binding of [3H]nitrendipine to rabbit ventricular membranes: modification by other Ca++ channel antagonists and by the Ca++ channel agonist Bay K 8644.
Janis RA; Sarmiento JG; Maurer SC; Bolger GT; Triggle DJ
J Pharmacol Exp Ther; 1984 Oct; 231(1):8-15. PubMed ID: 6208356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
